

ANSWERING REVIEWERS

April 30, 2015

Dear Editor,

Thank you for your efforts regarding our manuscript entitled “**The potentiality of immunotherapy against hepatocellular carcinoma**” previously submitted to your journal.

The issues raised by the reviewers were carefully checked, and our manuscript was modified according to their suggestions. Our manuscript was provided comprehensive editing services by AmEditor, Inc.

Please find enclosed the edited manuscript in Word format (file name: 17661-review).

Title: The potentiality of immunotherapy against hepatocellular carcinoma

Author: Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 17661

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Division of Cancer Immunotherapy,
Exploratory Oncology Research & Clinical Trial Center
National Cancer Center
6-5-1 Kashiwanoha, Kashiwa, 277-8577 Japan.
Phone Number: +81-4-7131-5490 Fax Number: +81-4-7133-6606
E-mail: tnakatsu@east.ncc.go.jp

Reviewer 1

We appreciate your helpful comments on our manuscript.

Our reply to each point is as follows.

Comments

1. Not presented: aims of the study.

According to the reviewer's direction, we added the following of the aim of this study on page 5, lines 22.

Here, we summarize the various types of HCC immunotherapy and argue that the newfound field of HCC immunotherapy might provide critical advantages in the effort to improve the treatment and thus prognosis for HCC.

2. Need to be worry with abbreviation (in p. 6 *regulatory DCs*, *CTLA-4*, *PD-L1* we find explanation only on p 10,12)

According to the reviewer's direction, we added the complete expression on page 8.9 as follows. And subsequent sentences were written with abbreviation.

dendritic cells (DCs)

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)

Programmed death-ligand 1 (PD-L1)

3.

Immunotherapy for HCC

Cytokine therapy

TAA targeted therapy

Immune checkpoint inhibitors

Cell transfer immunotherapy

In the end of this part will be very useful to introduce a table with short analysis of all of this information.

Tables and figures: tables is very big and not very informative.

We agree with this comment, so we added the immunotherapy type on a top of the table 1 and changed the order.

Reviewer 2

We appreciate your helpful comments on our manuscript.

According to the reviewer's direction (WJG-Manuscript_20150317100622-Reviewd.doc), we corrected each point.